PL397269A1 - Medical use of the substance of 5-(3-chlorophenyl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione - Google Patents

Medical use of the substance of 5-(3-chlorophenyl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

Info

Publication number
PL397269A1
PL397269A1 PL397269A PL39726911A PL397269A1 PL 397269 A1 PL397269 A1 PL 397269A1 PL 397269 A PL397269 A PL 397269A PL 39726911 A PL39726911 A PL 39726911A PL 397269 A1 PL397269 A1 PL 397269A1
Authority
PL
Poland
Prior art keywords
chlorophenyl
thione
dihydro
triazole
substance
Prior art date
Application number
PL397269A
Other languages
Polish (pl)
Other versions
PL220232B1 (en
Inventor
Tomasz Plech
Jarogniew J. Łuszczki
Monika Wujec
Original Assignee
Uniwersytet Medyczny W Lublinie
Instytut Medycyny Wsi Im. Witolda Chodźki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Medyczny W Lublinie, Instytut Medycyny Wsi Im. Witolda Chodźki filed Critical Uniwersytet Medyczny W Lublinie
Priority to PL397269A priority Critical patent/PL220232B1/en
Publication of PL397269A1 publication Critical patent/PL397269A1/en
Publication of PL220232B1 publication Critical patent/PL220232B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest zastosowanie 5-(3-chlorofenylo)-4-(4-chlorofenylo)-2,4-dihydro-3H-1,2,4-triazolo-3-tionu o wzorze 1 o dzialaniu przeciwdrgawkowym, do wytwarzania leku do leczenia napadów toniczno-klonicznych oraz napadów czesciowych z wtórnym lub bez wtórnego uogólnienia.The subject of the invention is the use of 5- (3-chlorophenyl) -4- (4-chlorophenyl) -2,4-dihydro-3H-1,2,4-triazol-3-thione of formula 1 with anticonvulsant activity in the manufacture of a medicament for treatment of tonic-clonic seizures and partial seizures with or without secondary generalization.

PL397269A 2011-12-07 2011-12-07 Medical use of the substance of 5-(3-chlorophenyl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione PL220232B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL397269A PL220232B1 (en) 2011-12-07 2011-12-07 Medical use of the substance of 5-(3-chlorophenyl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL397269A PL220232B1 (en) 2011-12-07 2011-12-07 Medical use of the substance of 5-(3-chlorophenyl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

Publications (2)

Publication Number Publication Date
PL397269A1 true PL397269A1 (en) 2013-06-10
PL220232B1 PL220232B1 (en) 2015-09-30

Family

ID=48539577

Family Applications (1)

Application Number Title Priority Date Filing Date
PL397269A PL220232B1 (en) 2011-12-07 2011-12-07 Medical use of the substance of 5-(3-chlorophenyl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione

Country Status (1)

Country Link
PL (1) PL220232B1 (en)

Also Published As

Publication number Publication date
PL220232B1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
UA109650C2 (en) BIS-ARLYZED ARILTRIAZOLONS AND THEIR APPLICATIONS
NZ618795A (en) Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
EA201400990A1 (en) INHIBITORS DIACYLGLYCERINACYLTRANSFERASE 2
DK2148670T3 (en) Titration of tapentadol
MX2013010795A (en) 1,3 oxazines as bace1 and/or bace2 inhibitors.
PL2947072T3 (en) 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases
EA201100335A1 (en) PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-ASSOCIATED DISEASES
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
PH12013502316A1 (en) Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors
UA115320C2 (en) Kinase inhibitors
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
ECSP088828A (en) 4-ANILINOQUINOLINA-3-CARBOXAMIDAS AS INHIBITORS OF THE QUINASE CSF-1R
BR112015026021A2 (en) combination therapy comprising a tor kinase inhibitor and n- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for cancer treatment
PH12015502365A1 (en) Bace1 inhibitors
NZ631022A (en) Cytotoxic agents for the treatment of cancer
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
MX2014005895A (en) Medicine for treatment and/or improvement of sepsis.
MD4215B1 (en) Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide
PL397269A1 (en) Medical use of the substance of 5-(3-chlorophenyl)-4-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
CL2008003062A1 (en) Compounds derived from spiro-conjugated pyrazoles, inhibitors of ksp kinesin activity; pharmaceutical composition comprising said compound; and use of the compound for the treatment of proliferative diseases.
PL397270A1 (en) The first medical use of the substance of 4-(4-bromophenyl)-5-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
MD20110040A1 (en) Inhibitors of human myeloid leukemia based on 2-[2-(pyridine-2-ilmethylidene)hydrazine]-1,3-benzothiazole and 2-[2-(1-pyridine-2-ilethylidene)hydrazine]-1,3-benzothiazole dihydrate
PL394231A1 (en) Medical application of 5-(3-chlorophenyl)-4 - (4-methylphenyl) -2,4-dihydro-3H-1,2,4-triazole-3-thione
PL397923A1 (en) New medical use of the substance of 5-(3-chlorophenyl)-4-(4-methylphenyl) -2-(morpholin-4-ylmethyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
PL397529A1 (en) New derivative of 4-(2-bromophenyl)-5-(4-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione, a method for its preparation and its first medical use